Table 1 Demographic information of participants and results for allergy marker testing.

From: Single-cell RNA sequencing reveals immunological link between house dust mite allergy and childhood asthma

Patient

Age (year)

Gender

Condition

Therapy (dosage)

Group ID

TIgE/IgE

sIgE

C01

4

Male

non-HDM

Seretide (50 μg/100 μg, 1 time daily)

C

288.4 IU/ml (TIgE)

Not detected

C02

4

Male

non-HDM

C

127.73 IU/ml (TIgE)

Not detected

C03

5

Female

non-HDM

C

89 IU/ml (IgE)

Not detected

T01

5

Male

HDM

T

818.3 IU/ml (TIgE)

DP 100 + IU/ml

DF 8.71 IU/ml

T02

5

Male

HDM

T

1350 IU/ml (TIgE)

DP 66.93 IU/ml

DF 18.63 IU/ml

T03

7

Female

HDM

T

1140 IU/ml(TIgE)

DP 100 + IU/ml

DF 100 + IU/ml

T04

11

Male

HDM

T

1233 IU/ml(TIgE)

DP 19.24 IU/ml

DF 89.05 IU/ml

T05

5

Female

HDM

O

1361 IU/ml (TIgE)

DP 100 + IU/ml

DF 94.66 IU/ml

BT 0.67 IU/ml

  1. (1) asthma diagnosis confirmed by the Guidelines for the Diagnosis and Optimal Management of Asthma in Children (2016)10, including recurrent respiratory symptoms (e.g., wheezing, dyspnea) and positive bronchial provocation test results; (2) age 4–11 years; (3) asthma medications (e.g., inhaled corticosteroids, bronchodilators) use ≤ 6 months and discontinuation ≥ 4 weeks prior to enrollment; and (4) stable, well-controlled asthma with no exacerbations in the preceding 4 weeks. For children aged < 5 years, diagnosis relied on ≥ 3 annual episodes of respiratory symptoms with documented improvement post-bronchodilator therapy.
Back to article page